



EMLc

ATC codes: L01CB01

|                          |   |
|--------------------------|---|
| Indication               | Malignant neoplasms of kidney, except renal pelvis<br>ICD11 code: 2D40.Z  |
| INN                      | Etoposide   |
| Medicine type            | Chemical agent  |
| List type                | Complementary (EML)<br>(EMLc)   |
| Formulations             | Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule ; 100 mg in vial powder for injection (as phosphate)<br>Oral > Solid: 100 mg capsule ; 50 mg capsule |
| EML status history       | First added in 2021 (TRS 1035)<br>Changed in 2023 (TRS 1049)  |
| Sex                      | All   |
| Age                      | Also recommended for children   |
| Therapeutic alternatives | The recommendation is for this specific medicine  |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .   |

Tags

Cancer

Wikipedia

Etoposide

DrugBank

Etoposide

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMCLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMCLc.

